Frontlight ResearchEarly access
Active, not recruitingPhase 3
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial
Key facts
- Who runs it
- Bayside Health
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 826 people, planned
- Started
- 1 Nov 2022
- Ended
- 31 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tranexamic Acid 100Mg/ml Inj Vial 10ml
- Placebo
- Record updated
- 31 December 2025
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adult patients scheduled for elective gastrointestinal (oesophageal, gastric, hepatobiliary, colorectal) surgery
- with 2 or more risk factors for complications:
- age ≥70 years,
- American Society of Anesthesiologists (ASA) physical status 3 or 4,
- heart failure, diabetes,
- chronic respiratory disease,
- obesity (BMI ≥30 kg/m2),
- vascular disease,
- preoperative haemoglobin <100 g/L,
- renal impairment (se. creatinine ≥150 micromol/L), or low albumin (<30 g/L)
- Written informed consent will be obtained. Exclusion criteria
- Poor spoken and/or written language comprehension,
- laparoscopic and other minor (eg. closure of stoma) surgery,
- pre-existing infection/sepsis,
- history of spontaneous pulmonary embolism or arterial thrombosis,
- current arterial or venous thrombosis,
- familial thrombophilia (e.g. Lupus anticoagulant, protein C deficiency, factor V Leiden),
- contraindication to TxA
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prophylactic TxA administration in patients undergoing major gastrointestinal surgery reduces the incidence of delirium after surgery when compared with placebo. The unifying hypothesis is that systemic and neuro-inflammation lead to neuronal injury and resultant postoperative delirium.
The 2 groups in the trial
- Tranexamic AcidExisting treatment, for comparison
12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
Treatment: Tranexamic Acid 100Mg/ml Inj Vial 10ml
- PlaceboPlacebo, for comparison
12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial (a Substudy of the TRIGS Trial)
- Record updated
- 31 December 2025